People who are African American have a two-fold increased risk of multiple myeloma compared to people who are White, and the incidence of multiple myeloma is higher in African Americans across all age groups. However, African American patients are more likely to have delays in diagnosis than White patients, as well as disparities in treatment—including reduced stem cell transplantation and participation in clinical trials—resulting in poorer outcomes. In this activity, Pritesh Patel, MD examines the current management of multiple myeloma in African American patients and offers his thoughts on ways to address treatment inequities in this patient population.
Oncology NPs, PAs, and nurses
This activity is supported by educational grants from AbbVie Inc., Amgen, Bristol-Myers Squibb Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Patel: consulting fees/fees for non-CME/CE services: Amgen, Celgene/BMS; fees for non-CME/CE services: Janssen.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 102521AJ-CT1